| Individual Sections |
| Overview of Section Contents | 2013-Apr-22 | 184.96 KB |
| Table of Contents | 2013-Apr-22 | 231.64 KB |
| Section 01: Introduction | 2013-Apr-22 | 145.82 KB |
| Section 02: Documentation Requirements | 2013-Apr-22 | 312.44 KB |
| Section 03: Participant Accrual and Retention | 2013-Apr-22 | 230.75 KB |
| Section 04: Informed Consent | 2013-Apr-22 | 272.44 KB |
| Section 05: Study Procedures | 2023-Apr-22 | 296.74 KB |
| Section 06: Counseling and Behavioral Considerations | 2013-Apr-23 | 457.21 KB |
| Section 07: Study Product Considerations for Non-Pharmacy Staff | 2013-Apr-22 | 940.74 KB |
| Section 08: Clinical Considerations | 2013-Apr-22 | 357.91 KB |
| Section 09: Adverse Event Reporting and Safety Monitoring | 2013-Apr-22 | 317.9 KB |
| Section 10: Laboratory Considerations | 2013-Apr-22 | 733.44 KB |
| Section 11: Data Collection | 2013-Apr-22 | 250.87 KB |
| Section 12: Data Communiques | 2013-Apr-22 | 10.54 KB |
| Section 13: Study Reporting Plan | 2013-Apr-22 | 23.82 KB |
